MOSCOW (Reuters) - Russia has completed clinical trials of a second potential vaccine against COVID-19, developed by Siberia's Vector Institute, the RIA news agency cited Russian consumer safety watchdog Rospotrebnadzor as saying on Wednesday.
The institute completed early-stage human trials, known as Phase II, earlier this month.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!